Sarissa Capital Acquisition Corp.
It is our intention to pursue prospective targets that are focused on health care and biopharma. Sarissa will target businesses with valuations of $500 million to $1 billion that have the potential to be substantially greater over time due to their underlying business characteristics and growth opportunities as a public company. Our focus will be on the health-care industry in the United States and other developed countries.
Alexander Denner, Ph.D., serves as the chairman and CEO of Sarissa Capital Acquisition Corp.
Our sponsor is an affiliate of Sarissa Capital Management LP, a leading health-care and biopharma investment firm. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two-decade career as a health-care investor at Morgan Stanley, Icahn Capital and Viking Capital.
|Address||660 Steamboat Rd Greenwich, CT 06830|
|View Prospectus:||Sarissa Capital Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$175.0 mil|
|Manager / Joint Managers||Cantor Fitzgerald|
|Expected To Trade:||10/21/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|